{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T01:04:18Z","timestamp":1766970258955,"version":"3.40.5"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>This study aimed to define real-world prescription patterns in Korea and compare the effectiveness of chronic obstructive pulmonary disease (COPD) medications. We used national claims data provided by the Health Insurance Review and Assessment Service in Korea and examined patients who were first diagnosed with COPD and started treatment between May 1, 2017, and April 30, 2018, with no change in drug regimen. Among 30,784 patients with COPD, long-acting \u03b2<jats:sub>2<\/jats:sub> agonist (LABA) combined with long-acting muscarinic antagonist (LAMA) (32.7%), inhaled corticosteroid-LABA (ICS\u2013LABA) (25.6%), LAMA (18.3%), ICS (5.8%), or LABA (4.6%) were prescribed as the first-choice inhalers. The use of LABA\u2013LAMA (hazard ratio [HR], 0.248\u20130.584), LAMA (HR, 0.320\u20130.641), ICS\u2013LABA (HR, 0.325\u20130.643), and xanthine (HR, 0.563\u20130.828) significantly reduced the total and severe exacerbation rates compared with no use of each medication. However, the use of ICS or LABA individually did not yield such effects. The continued use of LABA\u2013LAMA, LAMA, and ICS\u2013LABA showed a significant effect on exacerbation rate, whereas the long-term use of ICS, LABA, and xanthine did not. Moreover, some high doses of ICS\u2013LABA did not show significant effects. This real-world study revealed that LAMA and\/or LABA could be the first choice of therapy, as recommended by recent guidelines. However, ICS, xanthine, and high-dose ICS\u2013LABA are still being prescribed frequently as first-line drugs in Korea.<\/jats:p>","DOI":"10.1371\/journal.pone.0304362","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T17:29:24Z","timestamp":1718040564000},"page":"e0304362","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-1003","authenticated-orcid":true,"given":"Hye Jung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Uk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9916-1917","authenticated-orcid":true,"given":"Soyoung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-6948","authenticated-orcid":true,"given":"Hye Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Jin","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-0071","authenticated-orcid":true,"given":"Jae-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"4","key":"pone.0304362.ref001","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15412550600977478","article-title":"The clinical importance of dynamic lung hyperinflation in COPD.","volume":"3","author":"DE O\u2019Donnell","year":"2006","journal-title":"COPD"},{"issue":"6","key":"pone.0304362.ref002","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1183\/09031936.00048912","article-title":"The role of bronchodilator treatment in the prevention of exacerbations of COPD","volume":"40","author":"JA Wedzicha","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0304362.ref003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1164\/rccm.202009-3533SO","article-title":"Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease","volume":"203","author":"DMG Halpin","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"year":"2022","author":"A. BA Eduardo","article-title":"assessed at https:\/\/goldcopd.org\/2023-gold-report-2\/ (confirmed at Nov-12, 2022).","key":"pone.0304362.ref004"},{"issue":"7","key":"pone.0304362.ref005","first-page":"CD002991","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease.","volume":"2012","author":"IA Yang","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"pone.0304362.ref006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4046\/trd.2018.0029","article-title":"Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary.","volume":"81","author":"YB Park","year":"2018","journal-title":"Tuberc Respir Dis (Seoul)."},{"issue":"8","key":"pone.0304362.ref007","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"PM Calverley","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0304362.ref008","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MD.0b013e3181cafcd3","article-title":"Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease","volume":"89","author":"CC Shu","year":"2010","journal-title":"Medicine (Baltimore)."},{"issue":"7","key":"pone.0304362.ref009","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.200906-0937OC","article-title":"Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease","volume":"182","author":"Y To","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0304362.ref010","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/JAA.S379394","article-title":"A Comparison of the Effectiveness of Asthma Medications on Asthma Exacerbations in Real World National Cohort.","volume":"15","author":"HJ Park","year":"2022","journal-title":"J Asthma Allergy"},{"issue":"9","key":"pone.0304362.ref011","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.21037\/jtd.2017.08.109","article-title":"Current status of asthma care in South Korea: nationwide the Health Insurance Review and Assessment Service database.","volume":"9","author":"JY Choi","year":"2017","journal-title":"J Thorac Dis"},{"issue":"1","key":"pone.0304362.ref012","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12931-021-01684-1","article-title":"Influence of government-driven quality assessment program on patients with chronic obstructive pulmonary disease.","volume":"22","author":"HJ Park","year":"2021","journal-title":"Respir Res."},{"key":"pone.0304362.ref013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/COPD.S121687","article-title":"Trend of cost and utilization of COPD medication in Korea.","volume":"12","author":"J Lee","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"pone.0304362.ref014","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4046\/trd.2017.80.3.241","article-title":"Evaluation of Appropriate Management of Chronic Obstructive Pulmonary Disease in Korea: Based on Health Insurance Review and Assessment Service (HIRA) Claims.","volume":"80","author":"SM Chung","year":"2017","journal-title":"Tuberc Respir Dis (Seoul)."},{"issue":"1","key":"pone.0304362.ref015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","article-title":"Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.","volume":"20","author":"F Maltais","year":"2019","journal-title":"Respir Res."},{"issue":"12","key":"pone.0304362.ref016","first-page":"CD012620","article-title":"Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.","volume":"12","author":"Y Oba","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"pone.0304362.ref017","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ccm.2020.05.006","article-title":"Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Benefits and Risks.","volume":"41","author":"T Mkorombindo","year":"2020","journal-title":"Clin Chest Med."},{"issue":"11","key":"pone.0304362.ref018","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia.","volume":"68","author":"S Suissa","year":"2013","journal-title":"Thorax"},{"issue":"3","key":"pone.0304362.ref019","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00408-017-9990-8","article-title":"Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study","volume":"195","author":"JB Morjaria","year":"2017","journal-title":"Lung"},{"issue":"1","key":"pone.0304362.ref020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4068\/cmj.2019.55.1.47","article-title":"Adherence to the GOLD Guideline in COPD Management of South Korea: Findings from KOCOSS Study 2011\u20132018.","volume":"55","author":"TO Kim","year":"2019","journal-title":"Chonnam Med J."},{"issue":"2","key":"pone.0304362.ref021","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4046\/trd.2008.64.2.109","article-title":"Survey of COPD management among the primary care physicians in Korea.","volume":"64","author":"MJ Park","year":"2008","journal-title":"Tuberculosis and Respiratory Diseases"},{"issue":"5","key":"pone.0304362.ref022","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1183\/09031936.06.00072105","article-title":"Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment","volume":"27","author":"R Leigh","year":"2006","journal-title":"Eur Respir J"},{"issue":"11","key":"pone.0304362.ref023","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1053\/rmed.2001.1180","article-title":"Hospital re-admission in patients with acute exacerbation of chronic obstructive pulmonary disease.","volume":"95","author":"AC Lau","year":"2001","journal-title":"Respir Med."},{"key":"pone.0304362.ref024","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2016_71","article-title":"Xanthines and Phosphodiesterase Inhibitors","volume":"237","author":"D Spina","year":"2017","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"pone.0304362.ref025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.arbr.2015.06.014","article-title":"Chronic Use of Theophylline and Mortality in Chronic Obstructive Pulmonary Disease: A Meta-analysis.","volume":"52","author":"N Horita","year":"2016","journal-title":"Arch Bronconeumol."},{"key":"pone.0304362.ref026","first-page":"1769","article-title":"Bronchodilators use in patients with COPD.","volume":"10","author":"YH Dong","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"pone.0304362.ref027","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"R Casaburi","year":"2002","journal-title":"Eur Respir J"},{"issue":"2","key":"pone.0304362.ref028","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr\u2019s treatment with tiotropium","volume":"19","author":"W Vincken","year":"2002","journal-title":"Eur Respir J"},{"issue":"5","key":"pone.0304362.ref029","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4093\/dmj.2020.0207","article-title":"Data Configuration and Publication Trends for the Korean National Health Insurance and Health Insurance Review & Assessment Database.","volume":"44","author":"HK Kim","year":"2020","journal-title":"Diabetes Metab J"},{"key":"pone.0304362.ref030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2147\/COPD.S122989","article-title":"Natural course of early COPD.","volume":"12","author":"CK Rhee","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T17:29:45Z","timestamp":1718040585000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304362"}},"subtitle":[],"editor":[{"given":"Ai Theng","family":"Cheong","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304362","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,6,10]]}}}